This project is highly innovative as it will be the first to develop a mindfulness-based treatment as a first-line intervention tailored to target moral injury among combat-wounded veterans. In Study 1, the investigators recruited a small group of veterans to give feedback on the project. In Studies 2 and 3, the investigators will compare the newly developed mindfulness training to an equally intensive Educational Support condition. Further, if successful, this application may have the ability to adapted and extended to address common to other professions that experience moral injury.

Start Date01 Jun 2021

Sponsor / Collaborator

Old Dominion University

[+3]

NCT03947177

/ CompletedNot ApplicableIIT

Culturally Enhancing a Motivational Interviewing Intervention For Latinx Adolescents

The purpose of this study is to compare two versions of an intervention focused on teaching 10-14-year-old Latina/o adolescent's skills that will decrease the likelihood that they will use tobacco, alcohol, and other drugs. We are also interested in determining how cultural context is related to substance use and whether additional information about other tobacco products should be added to the GMIT intervention.

Start Date09 Sep 2019

Sponsor / Collaborator

Virginia Commonwealth University

[+3]

100 Clinical Results associated with The College of William & Mary

0 Patents (Medical) associated with The College of William & Mary

5,561

Literatures (Medical) associated with The College of William & Mary

01 Jul 2025·INTERNATIONAL JOURNAL OF MASS SPECTROMETRY

Gas phase proton affinities of proline-containing peptides. 2: ProCys, ProMet, ProSer, ProThr, ProTyr, ProPhe, and ProTrp

Author: Lamb, Madeleine ; Acoria, Paul ; Ton, Trinh ; Poutsma, Jennifer ; Messinger, Sophie ; Towler, Anna Grace ; Cardwell, Henry ; Valasquez, Mark ; Poutsma, John C. ; Moody, Daria ; Qian, Hao ; Brender A Brandis, Alexis ; Nicks, Laurel ; Huynh, Kathy ; Rastogi, Shantanu

The gas-phase proton affinities (PA) for a series of proline-containing dipeptides have been measured in an ESI triple quadrupole instrument using the extended kinetic method (EKM).Proton affinities of ProCys (1), ProMet (2), ProSer (3), ProThr (4), ProTyr (5), ProPhe (6), and ProTrp (7) were determined to be 966.9 ± 5.3, 987.9 ± 10.4, 978.4 ± 6.1, 978.3 ± 6.1, 993.9 ± 11.2, 985.1 ± 10.7, and 998.7 ± 7.6 kJ/mol, resp.Predictions for the proton affinities for 1-7 were also obtained through isodesmic calculations at the B3LYP/6-311++G(d,p)//B3LYP/6-31+G(d) level of theory.As with a previous study on the proton affinities of ProXxx dipeptides with aliphatic side chains (Cardwell et al., Int. J. Mass Spectrom.2025, 507, 117352) the agreement between theory and experiment is mixed.For the two dipeptides with sulfur in the side chain we find excellent agreement between the EKM and calculated proton affinities.For the three dipeptides with hydroxyl groups in the side chain, the exptl. values are between 7.2 and 13.2 kJ/mol larger than the computed proton affinities.Addnl. single point energy calculations on 3-5 with B3LYP/6-311++G(2df,2p) basis sets give predicted proton affinities that are somewhat smaller than those predicted with the (B3LYP/6-311++G9d,p) basis set.MP2/6-311z++G(2df,2p) single point energy calculations on 3 and 4 give calculated proton affinities within 1 kJ/mol of the B3LYP/6-311++G(d,p) values.It appears that the EKM values for 3-5 are systematically too high, possible o to the extrapolation required to obtain the isothermal point in the EKM workup due to the large protonation entropies of the dipeptides.This result is also seen to a lesser extent for ProPhe and ProTrp in which the EKM proton affinities are 5-6 kJ/mol larger than the calculated values.As with the aliphatic ProXxx dipeptides from our previous study, we recommend using the calculated proton affinities for 1-7 with the exptl. proton affinities as upper limits.

18 Jun 2025·JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Impact of Living in a Food Desert on Complications After Fracture Surgery

Article

Author: O’Hara, Nathan N. ; Stennett, Christina A. ; Della Rocca, Gregory J. ; Phillips, Joseph D. ; Wang, Yinzhou ; Brameier, Devon T. ; Pilson, Holly T. ; Chang, Gerard ; Weaver, Michael J. ; von Keudell, Arvind G. ; Gitajn, I. Leah ; Slobogean, Gerard P. ; Bergin, Patrick F. ; Sprague, Sheila

Background::

Food deserts—communities with limited access to healthy food—have been linked with poor surgical outcomes; however, their impact on orthopaedic trauma outcomes remains unknown. The aims of this study were to determine the prevalence of food desert residency among orthopaedic trauma patients and to investigate the impact of food desert residency on the rate of unplanned reoperation with use of a large, high-quality, prospectively collected dataset with adjudicated outcomes. We hypothesized that orthopaedic trauma patients would reside in food deserts at a higher rate than the general U.S. population and that living in a food desert would be independently associated with an increased rate of unplanned reoperation.

Methods::

We included all patients from the Aqueous-PREP and PREPARE trials who had documented ZIP codes. The primary outcome was unplanned reoperation within 1 year, and the secondary outcomes included the reasons for reoperation. Residing in a food desert was the independent variable and was defined by the United States Department of Agriculture (USDA). Census tracts were converted to ZIP codes in order to assign food access for an individual’s residence with use of the USDA Food Access Research Atlas.

Results::

Of the 2,607 patients included, 1,453 (55.7%) lived in a ZIP code containing a food desert compared with 49% of the U.S. population. Patients residing in a food desert were 42% female, 26.6% non-White, and 64% employed prior to injury, whereas patients not residing in a food desert were 41% female, 15% non-White, and 63% employed prior to injury, all of which was collected via patient self-report. Multivariable analysis demonstrated that living in a food desert was independently associated with 40% higher odds of unplanned reoperation (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.06 to 1.85; p = 0.019). This was driven by reoperation for delayed union or nonunion (OR, 1.75; 95% CI, 1.19 to 2.57; p = 0.004) and reoperation for a wound-healing complication (OR, 1.60; 95% CI, 1.01 to 2.54; p = 0.044).

Conclusions::

This study found a strong association between residing in a ZIP code containing a food desert and an increased rate of unplanned reoperation, which was primarily driven by delayed union or nonunion and wound-healing complications. Addressing nutritional deficiencies in this population may help to effectively triage the use of health-care resources. Further research should focus on clarifying specific deficiencies and assessing the effectiveness of targeted interventions.

Level of Evidence::

Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

18 Jun 2025·APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Survival and spread of engineered Mycobacterium smegmatis and associated mycobacteriophage in soil microcosms

Article

Author: Carline, Kate B. R. ; Fleeharty, Megan S. ; Tchadi, Bilalay V. ; Holley, Emma C. ; Saha, Margaret S. ; Shockey, Bjorn B.

ABSTRACT:

The inoculation of microbes into soil environments has numerous applications for improving soil quality and crop health; however, the ability of exogenous and engineered microbes to survive and spread in soil remains uncertain. To address this challenge, we assayed the survival and spread of Mycobacterium smegmatis , engineered with either plasmid transformation or genome integration, as well as its mycobacteriophage Kampy, in both sterilized and non-sterilized soil microcosms over a period of 49 days. Although engineered M. smegmatis and Kampy persisted in all soil microcosms, there was minimal evidence of spread to 5 cm away from the inoculation site. There was a higher prevalence of Kampy observed in sterilized soil than in non-sterilized soil, suggesting a detrimental effect of the native soil biotic and viral community on the ability of this phage to proliferate in the soil microcosm. Additionally, a higher abundance of the genome-integrated bacteria relative to the plasmid-carrying bacteria, as well as evidence for loss of plasmid over the duration of the experiment, suggests a burden associated with bacteria harboring plasmids, although plasmids were still retained across 49 days. To our knowledge, this is the first study to simultaneously measure the persistence and spread of bacteria and their associated phage in both sterilized and non-sterilized soil microcosms, employing bacteria with plasmid-based and genome-integrated engineered circuits. As such, this study provides a novel understanding of challenges associated with the deployment of bioengineered microbes into soil environments.

IMPORTANCE:

Healthy soil is essential to sustain life, as it provides habitable land, enables food production, promotes biodiversity, sequesters and cycles nutrients, and filters water. Given the prevalence of soil degradation, treatment of soil with microbes that promote soil and crop health could improve global soil sustainability; furthermore, the application of bioengineering and synthetic biology to these microbes allows fine-tunable and robust control of gene-of-interest expression. These solutions require the introduction of bacteria into the soil, an environment in which abundant competition and often limited nutrients can result in bacterial death or dormancy. This study employs Mycobacterium smegmatis as a chassis alongside its bacteriophage Kampy in soil microcosms to assess the ability of non-native microbes to survive and spread in soil. Insights from this experiment highlight important challenges, which must be overcome for successful deployment of engineered microbes in the field.

News (Medical) associated with The College of William & Mary

31 Jul 2024

·www.prnewswire.com

Is Wharton's jelly the new gold standard for hip cartilage repair?

New study shows promising results for allograft from Regenative Labs PENSACOLA, Fla., July 31, 2024 /PRNewswire/ -- More than 350,000 hip replacements are performed in the U.S. each year. Typically, patients in need of hip cartilage repairs seek minimally invasive options first, making Wharton's jelly a promising alternative for musculoskeletal defects. Continue Reading Albert Lai MD A recent study, titled Retrospective Evaluation of Cryopreserved Human Umbilical Cord Tissue Allografts in the Supplementation of Cartilage Defects Associated with Hip Osteoarthritis, showed that patients reported less pain and stiffness when receiving an application of a Wharton's Jelly allograft from Regenative Labs. The overall objective of this study was to evaluate the improvement of patient-reported pain, quality of life, and functionality scales after applying Wharton's jelly in hip defects. Dr. Albert Lai of Desert Pain Specialists and Centers of Rehabilitation and Pain Medicine in California and Dr. Conrad Tamea of Orthopedic Associates of Tampa Bay participated in the study. A double board-certified physician with specialties in physical medicine rehabilitation and pain medicine, Dr. Lai said the Wharton's jelly therapy was providing relief for their patients. "Incorporating Wharton's jelly into our practice has provided an effective conservative option for patients with hip defects that outperforms conventional therapies," said Dr. Lai. "Using the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life." The study follows 69 patients with hip defects from 26 private practices who received an application of a Wharton's jelly allograft from Regenative Labs. Prior to the study, these patients had failed at least 8 weeks of conservative treatment. Patient outcomes were tracked on a 90-day calendar using three scales including the Numeric Pain Rating Scale (NPRS), Quality of Life Scales (QOLS), and the Western Ontario and McMaster University Arthritis Index (WOMAC) covering pain, stiffness, and functionality. There were statistically significant differences between the initial application and day 90 for the NPRS and WOMAC scales. The application of Wharton's jelly allografts in this retrospective cohort was observed to promote decreases in patient-reported NPRS scores, pain and stiffness and to improve function. These improvements were consistent across age groups but were most notable for the elderly, who generally have a slower and less effective recovery rate after conservative treatment and surgical procedures. Because of the success shown by NPRS and WOMAC in decreasing pain in the elderly population, Regenative Labs CEO Tyler Barrett said more studies are warranted to evaluate the safety and efficacy of Wharton's Jelly, specifically in patients older than 65. "Total hip replacements by Medicare alone are estimated to make up somewhere between $7 billion to $10 billion in annual healthcare expenditures in the U.S. It's clear that the need for this type of research is necessary and quite frankly overdue," said Barrett. The positive results from this study and the current literature provide a foundation to study applications of Wharton's Jelly in other musculoskeletal injuries to ultimately improve the quality of life and reduce the economic burden of multiple conservative treatments or surgical procedures. Dr. Tamea said Wharton's jelly allografts have reduced pain and stiffness for his patients — and in some cases — reduced the need for surgery. "As a board-certified Orthopedic Surgeon with more than 25 years of operative experience, I can say after using Wharton's jelly allografts in more than 200 cases, I have found them to be extremely beneficial to my patients," said Dr. Tamea. "Orthopedic applications using Wharton's jelly — including in the knee, shoulder, hip, and spine — are more often than not preventing the need for surgery that results in a prolonged recovery time, lost wages and great financial cost." Barrett and the Regenative Labs' team hope to enlist physicians to take part in studies regarding uncovered uses. Physicians will have their outcomes highlighted, furthering the understanding of regenerative medicine and uncovering new applications for this groundbreaking field. Physicians can contact Regenative Labs to get their practice involved today. Read the full study here. Wharton's jelly explained: About Regenative Labs Regenative Labs produces regenerative medicine products to address the root cause of a patient's debilitating situation using Wharton's Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides effective and minimally invasive options for patients. Regenative Labs' expert product research and development team complies with FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at About Dr. Albert Lai A southern Californian native, Dr. Lai completed his medical training at Tufts University, where he subsequently served as a clinical instructor. He is board certified in Physical Medicine and Rehabilitation. He also holds board certifications in Pain Medicine and Independent Medical Examiners. Dr. Lai has served as the managing partner at the offices of Desert Pain & Rehabilitation Associates based in Rancho Mirage for the past 18 years and as medical director of Centers of Rehabilitation and Pain Medicine in Placentia, California. Learn more at the Centers of Rehabilitation website: Pain Clinic Orange County | Professional Pain Management in OC (ocpain.net) About Dr. Conrad Tamea Dr. Tamea is a board-certified Orthopedic Surgeon, who now focuses solely on regenerative medicine. He received his education from the College of William and Mary, Drexel University, Hahnemann Medical University, and the University of Kansas Orthopedic Residency Program. Dr. Tamea utilizes his knowledge and experience from over three decades as a surgeon and over a decade of regenerative medicine and combines this knowledge with state-of-the-art equipment at his clinic at Orthopedic Associates of Tampa Bay. SOURCE Regenative Labs

Clinical ResultExecutive Change

03 Jun 2024

·www.prnewswire.com

The Inner Circle Acknowledges, Randi Leigh Sessoms Lassiter as a Distinguished Healthcare Provider

MINNEAPOLIS, June 3, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery. Dr. Lassiter prepared for her vocation attending the College of William and Mary where she earned a Bachelor's degree. She then attended Duke University and received a Medical Degree; completed a residency at the Medical College of Georgia; and a fellowship at Nicholas Children's Hospital. Continue Reading Randi Leigh Sessoms Lassiter Dr. Lassiter currently works at M Health Fairview Pediatric Specialty Clinic Discovery & M Health Fairview Pediatric Specialty Clinic Woodbury where she practices as a pediatric general surgeon who treats children who have an illness, injury or disease that requires surgery. Her clinical interests include congenital gastrointestinal and abdominal disorders; congenital lung lesion; management of solid tumors in infants and children; pediatric trauma; vascular access; pediatric endocrine surgery; and chest wall deformities. A published author, the doctor maintains professional affiliation with the ACS and APSA. When reflecting on her illustrious career, Dr. Lassiter attributes her success to following her philosophy of giving her patients the highest quality of care without compromise and the support of her mentor, Dr. Robin Hatley. Among the many journals the doctor reads to stay abreast of the latest research, she most enjoys the American Pediatric Surgical Association. Dr. Lassiter has many highlights in her career and considers becoming board certified in 2023 and finishing her fellowship as her greatest career accomplishment. She would like to dedicate this honor to her dear parents, Kaleta and Randolph Lassiter and thank them for their love and support. Aside from her medical pursuits, the doctor enjoys travel and photography. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

Executive Change

06 May 2024

·www.prnewswire.com

The Inner Circle Acknowledges, Randi Leigh Sessoms Lassiter as a Distinguished Healthcare Provider

MINNEAPOLIS, May 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Randi Leigh Sessoms Lassiter is acknowledged as a Distinguished Healthcare Provider for her contributions to the field of Pediatric Surgery. Dr. Lassiter prepared for her vocation attending the College of William and Mary where she earned a Bachelor's degree. She then attended Duke University and received a Medical Degree; completed a residency at the Medical College of Georgia; and a fellowship at Nicholas Children's Hospital. Continue Reading Randi Leigh Sessoms Lassiter Dr. Lassiter currently works at M Health Fairview Pediatric Specialty Clinic Discovery & M Health Fairview Pediatric Specialty Clinic Woodbury where she practices as a pediatric general surgeon who treats children who have an illness, injury or disease that requires surgery. Her clinical interests include congenital gastrointestinal and abdominal disorders; congenital lung lesion; management of solid tumors in infants and children; pediatric trauma; vascular access; pediatric endocrine surgery; and chest wall deformities. A published author, the doctor maintains professional affiliation with the ACS and APSA. When reflecting on her illustrious career, Dr. Lassiter attributes her success to following her philosophy of giving her patients the highest quality of care without compromise and the support of her mentor, Dr. Robin Hatley. Among the many journals the doctor reads to stay abreast of the latest research, she most enjoys the American Pediatric Surgical Association. Dr. Lassiter has many highlights in her career and considers becoming board certified in 2023 and finishing her fellowship as her greatest career accomplishment. She would like to dedicate this honor to her dear parents, Kaleta and Randolph Lassiter and thank them for their love and support. Aside from her medical pursuits, the doctor enjoys travel and photography. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

Executive Change

100 Deals associated with The College of William & Mary

100 Translational Medicine associated with The College of William & Mary

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 06 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WM-101	Alzheimer Disease More	Clinical
AUX-101 (Auxulin Pharmaceuticals)	Diabetes Mellitus, Type 1 More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis